New Blood Test Could Help Track MS Progression More Reliably

Researchers comparing two protein biomarkers found that serum glial fibrillary acidic protein may better predict disease progression in multiple sclerosis patients than the current standard. The finding could help doctors identify patients at risk of worsening disease and adjust treatment strategies earlier, potentially reducing disability and improving patient outcomes.

Originaltitel: Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis